Xspray Pharma Management
Management criteria checks 2/4
Xspray Pharma's CEO is Per Andersson, appointed in Jan 2006, has a tenure of 18.42 years. total yearly compensation is SEK3.74M, comprised of 70.5% salary and 29.5% bonuses, including company stock and options. directly owns 0.74% of the company’s shares, worth SEK15.14M. The average tenure of the management team and the board of directors is 0.6 years and 5.1 years respectively.
Key information
Per Andersson
Chief executive officer
kr3.7m
Total compensation
| CEO salary percentage | 70.5% |
| CEO tenure | 18.4yrs |
| CEO ownership | 0.7% |
| Management average tenure | less than a year |
| Board average tenure | 5.1yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -kr213m |
| Dec 31 2023 | kr4m | kr3m | -kr180m |
| Sep 30 2023 | n/a | n/a | -kr180m |
| Jun 30 2023 | n/a | n/a | -kr170m |
| Mar 31 2023 | n/a | n/a | -kr148m |
| Dec 31 2022 | kr4m | kr2m | -kr132m |
| Sep 30 2022 | n/a | n/a | -kr128m |
| Jun 30 2022 | n/a | n/a | -kr114m |
| Mar 31 2022 | n/a | n/a | -kr102m |
| Dec 31 2021 | kr3m | kr2m | -kr97m |
| Sep 30 2021 | n/a | n/a | -kr60m |
| Jun 30 2021 | n/a | n/a | -kr57m |
| Mar 31 2021 | n/a | n/a | -kr56m |
| Dec 31 2020 | kr3m | kr2m | -kr52m |
| Sep 30 2020 | n/a | n/a | -kr56m |
| Jun 30 2020 | n/a | n/a | -kr55m |
| Mar 31 2020 | n/a | n/a | -kr49m |
| Dec 31 2019 | kr3m | kr2m | -kr46m |
| Sep 30 2019 | n/a | n/a | -kr41m |
| Jun 30 2019 | n/a | n/a | -kr34m |
| Mar 31 2019 | n/a | n/a | -kr30m |
| Dec 31 2018 | kr2m | kr2m | -kr23m |
| Sep 30 2018 | n/a | n/a | -kr17m |
| Jun 30 2018 | n/a | n/a | -kr16m |
| Mar 31 2018 | n/a | n/a | -kr8m |
| Dec 31 2017 | kr2m | kr1m | -kr14m |
Compensation vs Market: Per's total compensation ($USD355.65K) is below average for companies of similar size in the UK market ($USD730.26K).
Compensation vs Earnings: Per's compensation has increased whilst the company is unprofitable.
CEO
Per Andersson (57 yo)
18.4yrs
Tenure
kr3,743,000
Compensation
Dr. Per Andersson Ph.D. has been the Chief Executive Officer of Xspray Pharma AB (publ) since 2006. Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. Dr. Andersson joined XSp...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 18.4yrs | kr3.74m | 0.74% SEK 15.1m | |
| Co-Founder and Science Director | no data | no data | no data | |
| Acting Chief Financial Officer | less than a year | no data | no data | |
| Vice President of Operations | no data | no data | no data | |
| Senior Advisor & Head of IR | less than a year | no data | 0.030% SEK 612.1k | |
| Senior Vice President of Legal | less than a year | no data | 0.0066% SEK 133.6k | |
| Senior Vice President of Research & Development | 6.4yrs | no data | 0.011% SEK 222.6k | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Senior Vice President of Regulatory Affairs | less than a year | no data | 0.0055% SEK 111.4k | |
| Senior Vice President of Intellectual Property | 6.4yrs | no data | 0.11% SEK 2.2m |
0.6yrs
Average Tenure
56.5yo
Average Age
Experienced Management: XSPRAS's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 9.4yrs | kr323.00k | 0.11% SEK 2.3m | |
| Independent Director | 9.4yrs | kr270.00k | no data | |
| Chairman | 3.1yrs | kr510.00k | 2.1% SEK 42.8m | |
| Independent Director | 7.4yrs | kr253.00k | 0% SEK 0 | |
| Independent Director | 5.1yrs | kr270.00k | 0% SEK 0 | |
| Director | 3.1yrs | kr253.00k | 2.63% SEK 53.6m | |
| Independent Director | 2.1yrs | kr218.00k | 0.036% SEK 742.0k |
5.1yrs
Average Tenure
66yo
Average Age
Experienced Board: XSPRAS's board of directors are considered experienced (5.1 years average tenure).